EP1624883A4 - Zusammensetzungen und verfahren im zusammenhang mit der produktion von erythropoietin - Google Patents

Zusammensetzungen und verfahren im zusammenhang mit der produktion von erythropoietin

Info

Publication number
EP1624883A4
EP1624883A4 EP04759353A EP04759353A EP1624883A4 EP 1624883 A4 EP1624883 A4 EP 1624883A4 EP 04759353 A EP04759353 A EP 04759353A EP 04759353 A EP04759353 A EP 04759353A EP 1624883 A4 EP1624883 A4 EP 1624883A4
Authority
EP
European Patent Office
Prior art keywords
erythropoietin
compositions
production
methods associated
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04759353A
Other languages
English (en)
French (fr)
Other versions
EP1624883A2 (de
Inventor
Bellamkonda K Kishore
Christof Westenfelder
Jorge Isaac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of EP1624883A2 publication Critical patent/EP1624883A2/de
Publication of EP1624883A4 publication Critical patent/EP1624883A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04759353A 2003-04-09 2004-04-09 Zusammensetzungen und verfahren im zusammenhang mit der produktion von erythropoietin Withdrawn EP1624883A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46194103P 2003-04-09 2003-04-09
PCT/US2004/011003 WO2004091495A2 (en) 2003-04-09 2004-04-09 Compositions and methods related to production of erythropoietin

Publications (2)

Publication Number Publication Date
EP1624883A2 EP1624883A2 (de) 2006-02-15
EP1624883A4 true EP1624883A4 (de) 2008-11-26

Family

ID=33299880

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04759353A Withdrawn EP1624883A4 (de) 2003-04-09 2004-04-09 Zusammensetzungen und verfahren im zusammenhang mit der produktion von erythropoietin

Country Status (5)

Country Link
US (1) US8084424B2 (de)
EP (1) EP1624883A4 (de)
AU (1) AU2004229465B2 (de)
CA (1) CA2521979A1 (de)
WO (1) WO2004091495A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004534A (es) * 2001-11-16 2004-08-11 Childrens Medical Center Aumento de la funcion de un organo.
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
JP2007514673A (ja) * 2003-12-19 2007-06-07 エフ．ホフマン−ラ　ロシュ　アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
CA2610265A1 (en) * 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
US9580688B2 (en) * 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
CA2688265C (en) * 2007-06-08 2021-02-16 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US20100310504A1 (en) * 2007-09-26 2010-12-09 Lowe Scott W Methods for treating fibrosis by modulating cellular senescence
EP2358375B1 (de) * 2008-11-12 2013-07-24 Tengion, Inc. Isolierte nierenzellen und verwendungen dafür
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
KR102302069B1 (ko) 2010-11-10 2021-09-14 인리젠 장기 확대를 위한 주사가능 제제
EP2767279B1 (de) * 2011-10-12 2018-12-12 SBI Pharmaceuticals Co., Ltd. Mittel zur förderung einer erythropoietin-produktion
CN107002033B (zh) 2014-10-06 2021-08-10 奥加诺沃公司 工程化肾组织、其阵列及其制备方法
RU2611401C1 (ru) * 2015-10-28 2017-02-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ получения лекарственного средства с эритропоэтином местного действия
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
RU2699663C1 (ru) * 2019-06-03 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) Средство в виде геля с эритропоэтином, обладающее репаративной и антиоксидантной активностью

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321898A1 (fr) * 1975-08-26 1977-03-25 Taiho Pharmaceutical Co Ltd Medicament contenant un poly-(amino-acide)
US4526888A (en) * 1983-04-29 1985-07-02 Bristol-Myers Company Nephrotoxicity inhibitors for aminoglycoside antibiotics
WO1989004668A1 (en) * 1987-11-13 1989-06-01 The Salk Institute For Biological Studies Potentiation of erythropoiesis
EP0388799A2 (de) * 1989-03-19 1990-09-26 Interpharm Laboratories Ltd. Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5955422A (en) * 1983-12-13 1999-09-21 Kirin-Amgen, Inc. Production of erthropoietin
WO2000027997A1 (en) * 1998-11-06 2000-05-18 Sterrenbeld Biotechnologie North America, Inc. Method for the massive culture of cells producing recombinant human erythropoietin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106760A (en) * 1983-02-04 1992-04-21 Kirin-Amgen ATCC HB8209, its monoclonal antibody to erythropoietin and assay using same
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4935350A (en) * 1985-11-18 1990-06-19 Amgen Materials and methods for controlling plasmid copy number and stability
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
WO1992019239A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
US5482924A (en) * 1991-05-06 1996-01-09 Centre National De La Recherche Proteinaceous compositions having an activity on erythropoiesis
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US6080557A (en) * 1996-06-10 2000-06-27 Immunex Corporation IL-1/TNF-α-activated kinase (ITAK), and methods of making and using the same
IN184589B (de) * 1996-10-16 2000-09-09 Alza Corp
AUPO888097A0 (en) * 1997-08-29 1997-09-25 Biotech Australia Pty Limited Cross-linked particles
CA2401327C (en) 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
EP2105141B1 (de) * 2001-03-28 2012-08-08 Helix Biomedix, Inc. Kurze bioaktive Peptide und Verwendungsverfahren
US20030108556A1 (en) * 2001-06-08 2003-06-12 Mekalanos John J. Therapeutic uses of polyvalent compositions in infectious diseases
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030219407A1 (en) * 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321898A1 (fr) * 1975-08-26 1977-03-25 Taiho Pharmaceutical Co Ltd Medicament contenant un poly-(amino-acide)
US4526888A (en) * 1983-04-29 1985-07-02 Bristol-Myers Company Nephrotoxicity inhibitors for aminoglycoside antibiotics
US5955422A (en) * 1983-12-13 1999-09-21 Kirin-Amgen, Inc. Production of erthropoietin
WO1989004668A1 (en) * 1987-11-13 1989-06-01 The Salk Institute For Biological Studies Potentiation of erythropoiesis
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
EP0388799A2 (de) * 1989-03-19 1990-09-26 Interpharm Laboratories Ltd. Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
WO2000027997A1 (en) * 1998-11-06 2000-05-18 Sterrenbeld Biotechnologie North America, Inc. Method for the massive culture of cells producing recombinant human erythropoietin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BELLAMKONDA K. KISHORE ET AL: "Mechanism of the Thesaurismosis and Altered Lysosomal dynamics Induced by Poly-D-Glutamic Acid in Kidney Proximal Tubular Cells", LABORATORY INVESTIGATION, vol. 74, no. 6, 1996, pages 1025 - 1037, XP008097501 *
BELLAMKONDA K. KISHORE ET AL: "Poly-D-Glutamic Acid induces an Acute Lysosomal Thesaurismosis of Proximal Tubules and a Marked Proliferation of Intestitium in Rat Kidney", LABORATORY INVESTIGATION, vol. 74, no. 6, 1996, pages 1013 - 1023, XP008097500 *
KURTZ A ET AL: "ERYTHROPOIETIN PRODUCTION BY FETAL MOUSE LIVER CELLS IN RESPONSE TO HYPOXIA AND ADENYLATE CYCLASE STIMULATION", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 118, no. 2, 1 January 1986 (1986-01-01), pages 567 - 572, XP009031931, ISSN: 0013-7227 *
KURTZ A ET AL: "ERYTHROPOIETIN PRODUCTION IN CULTURES OF RAT RENAL MESANGIAL CELLS", CONTRIBUTIONS TO NEPHROLOGY, KARGER, BASEL, CH, vol. 50, 1 January 1986 (1986-01-01), pages 175 - 187, XP001181824, ISSN: 0302-5144 *
MASUDA S ET AL: "Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 746, no. 1/02, 23 January 1997 (1997-01-23), pages 63 - 70, XP002098357, ISSN: 0006-8993 *
TODD J AND HOTTENDORF G: "Poly-L-Aspartic Acid Orotects Cultured Human Proximal Tubule Cells Against Aminoglycoside-Induced Electrophysiological Alterations", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 90, no. 2-3, 1 January 1997 (1997-01-01), pages 217 - 221, XP002985513, ISSN: 0378-4274 *
WANG M-D ET AL: "Erythropoietin production from CHO cells grown by continuous culture in a fluidized-bed bioreactor", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 77, no. 2, 20 January 2002 (2002-01-20), pages 194 - 203, XP002250294, ISSN: 0006-3592 *

Also Published As

Publication number Publication date
US20070078084A1 (en) 2007-04-05
AU2004229465B2 (en) 2010-04-29
WO2004091495A3 (en) 2005-05-06
WO2004091495A2 (en) 2004-10-28
CA2521979A1 (en) 2004-10-28
AU2004229465A1 (en) 2004-10-28
EP1624883A2 (de) 2006-02-15
US8084424B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
EP1677822A4 (de) 4'-thionucleoside und oligomere verbindungen
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
NO2017051I2 (no) Kariprazin, eventuelt i form av et salt
EP1853777A4 (de) Übergangsprofil und installationsverfahren dafür
EP1620676A4 (de) Beleuchtungsverfahren und -systeme
EP1696784A4 (de) Biokonjugierte nanostrukturen, verfahren zu ihrer herstellung und anwendungsverfahren dafür
FR2853498B1 (fr) Article d'habillement
EP1562742A4 (de) Mikrostrukturen und herstellungsverfahren dafür
ITMI20020435A1 (it) Attrezzo oscillante atto a simulare l'esercizio di voga
EP1628993A4 (de) Verfahren und zusammensetzungen zur rna-interfrenz
IS7829A (is) Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
EP1778219A4 (de) Ascophyllum-zusammensetzungen und verfahren
EP1611147A4 (de) 6"-amino-6"-deoxygalactosylceramide
EP1558772A4 (de) Titanherstellung
DK1509529T3 (da) Estere på camptotheciners position 20
DE60228468D1 (de) Kunstzähne und ihre herstellung
DE60220436D1 (de) Microkügelchen mit einem pleuromutilin-derivat
EP1768691A4 (de) Aequorin enthaltende zusammensetzungen und anwendungsverfahren dafür
EP1466168A4 (de) Ammoniumionophor
EP1811839A4 (de) Verfahren und zusammensetzungen in verbindung mit esculentosid a
EP1677784A4 (de) Antivirale indol-zusammensetzungen und verfahren
EP1598076A4 (de) Interleukin 6 produktionshemmer
EP1535067A4 (de) Papsss als modifikatoren des axin-wegs und verwendungsverfahren
FR2849056B1 (fr) Mannuronane c5-epimerases d'algues brunes, procedes d'obtention et utilisations
FR2852042B1 (fr) Piece d'aretier

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051108

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081023

17Q First examination report despatched

Effective date: 20090520

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161101